Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases

Author(s): Sylvia S. Singh, Peter M. Kang

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 18 , 2011

Become EABM
Become Reviewer
Call for Editor


Apoptosis or progress of programmed cell death is a tightly regulated process which plays an important role in various cardiovascular diseases particularly in myocardial infarction, reperfusion injury, and heart failure. Over the past two decades, investigations of several pathways have broadened our understanding of programmed cell death. Many anti-apoptotic interventions have targeted ischemia- reperfusion, however only a limited number have been considered at the chronic stage of heart failure. Endogenous inhibitors, caspase inhibitors, PARP-1 inhibitors, as well as various other agents have been implicated as anti-apoptotic interventions. This review summarizes the apoptotic pathways associated with heart failure, discusses the current anti-apoptotic interventions available and reviews the clinical implications.

Keywords: Apoptosis, Heart failure, Caspase inhibitors, Endogenous inhibitors, Anti-apoptotic interventions, Caspase, Endogenous, zymogens, Cardiovascular, congestive, executioner, hypertrophy, diabetes, systolic, reperfusion, myocardial, mitochondrial, proteases

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [1783 - 1793]
Pages: 11
DOI: 10.2174/138161211796390994
Price: $65

Article Metrics

PDF: 18